Professor Cao Deliang's team in Nanhua University developed my country's first liver cancer diagnostic reagent to fully independent intellectual property rights

Professor Cao Deliang is doing experiments

Recently, after more than 10 years of deep cultivation, Professor Cao Deliang of Nanhua University successfully developed a new type of primary liver cancer diagnostic kit "Aldarian ketone Restrans 1B10 measurement kit (time resolution of fluorescent immune analysis method)" and obtained the National Drug Administration 3 Class diagnostic reagent registration approval. This is my country's first liver cancer diagnostic kit with complete independent intellectual property rights, and it is also the world's first liver cancer diagnostic product based on aldaone -based ketone -based 1B10 (AKR1B10).

Screenshot of the approval, the company's legal person is Professor Cao Deliang

The currently widely used liver cancer diagnostic symbol is nail protein (AFP). Through large -scale clinical research, Cao Deliang discovered that AKR1B10 protein, as a marker of liver cancer, is significantly better than AFP, which is mainly reflected in three aspects: one is more sensitive and easier to identify patients with asymptomatic early liver cancer; , Low-diagnosis and misdiagnosis rates; Third, the time to reflect the changes in the condition is 6-7 times faster than AFP. Patients with liver cancer patients can learn the surgical effect earlier after surgery. in accordance with.

In 2019, the research results of AKR1B10 protein as a blood cancer signs of liver cancer were published on the classic and authoritative journal "Hepatology" in the field of liver disease in the field of liver disease.

Professor Cao Deliang is a student at the 79th clinical medicine at the original Hengyang Medical College (now Nanhua University). He is now a high -level talent in Nanhua University. In 1995, Cao Deliang discovered a new gene in the study. He realized that this may be a new field of research. Since then, he has taken root in the study. He took the lead in cloning and identified the gene, that is, the aldosterone restoration enzyme 1B10 (ALDO-Keto Reductase 1B10, AKR1B10), and conducted in-depth systematic research on its biological functions, expression regulation, role and mechanism in tumors, etc. And found that AKR1B10 can become liver cancer markers, which are used in the screening, auxiliary diagnosis and monitoring of liver cancer. In the field of AKR1B10, Professor Cao Deliang obtained 4 invention patents and published 31 high -level SCI papers, which is a leading position worldwide.

AKR1B10 protein crystal structure diagram

The three types of diagnostic reagents approved this time are the highest classification of internal and external diagnostic reagents in my country, and the requirements are the most strict. Obtaining registration approval means that it can be directly applied to the clinic. "This is a diagnostic product with clinical prospects. We will continue to expand clinical research and accumulate more AKR1B10 for data screening, early diagnosis, evaluation of diseases, monitoring recurrence and other data. , Healthy Hunan, benefit the people and society. "Cao Deliang said firmly.

Professor Cao Deliang (second from right) discussed with some members of the team

According to data released by GLOBOCAN2018, the number of new annual cases of global liver cancer reached 841,000, ranking 6th in malignant tumors, 782,000 deaths, and second in malignant tumors. Liver cancer is particularly high in my country. The annual new cases have 466,000 people and 422,000 deaths, accounting for 55.4%and 53.9%of the world's worldwide. They are the 4th common malignant tumors and the cause of death to death. Cao Deliang pointed out that the incidence of liver cancer, high mortality, and hidden onset, early diagnosis and early treatment are the key to improving patients' survival. It will be committed to the establishment of the early treatment of early treatment of liver cancer, and continue to explore and work for the early diagnosis and early treatment of liver cancer, help more patients with liver cancer patients, and realize scientific research to the country. (Correspondent Xia Wenhui Zheng Haixin)

- END -